Lumen Bioscience Inc. plans to use its $11.2 million in series A money – supplemented by $1.8 million in the form of a grant from the U.S. Department of Energy – to explore the use of spirulina in making therapeutic products, CEO and co-founder Brian Finrow told BioWorld Insight.